Multireceptor atypical antipsychotic drugs

作者: Herbert Y. Meltzer

DOI: 10.1007/978-3-0348-8448-8_10

关键词: Antipsychotic AgentClozapineNeuroleptic malignant syndromeTardive dyskinesiaAtypical antipsychoticAntipsychoticSchizophreniaBioinformaticsMedicineHaloperidol

摘要: The atypical antipsychotic drugs are those agents which produce fewer extrapyramidal side-effects (EPS) at clinically effective anti-psychotic doses than do the typical neuroleptic [23]. This definition of an drug is still controversial [3]. Various authorities have suggested that term be dropped completely and some other general name used, e.g. novel antipsychotics, while others propose broadened to include features beyond efficacy low EPS, specific pharmacological such as multi-receptor activity, in treatment-resistant schizophrenia, ability improve negative symptoms [3 4]. Clozapine prototypical [5]. It was designated because it differed from were available time its introduction 1960 neuroleptics produced catalepsy rodents EPS man relevant clozapine did not [6]. widely used by preclinical investigators refer their efforts understand biological basis for difference between drug, haloperidol, with regard effects on limbic nigrostriatal dopaminergic systems, probable sites action respectively [7]. Thus, there has been much historical precedent atypicality focuses system differences drugs. Furthermore, acute chronic most significant first generation influence upon compliance, effect, turn relapse rehospitalization [8], well sometimes fatal malignant syndrome, cause tardive dyskinesia [9]. What complicated issue essence discovery many advantages including no known dyskinesia, improvement symptoms, decreased risk suicide, cognition, important [10] (see Naber et al., this volume].

参考文章(91)
Ereshefsky L, Pharmacokinetics and drug interactions: update for new antipsychotics. The Journal of Clinical Psychiatry. ,vol. 57, pp. 12- 25 ,(1996)
Ott Br, Friedman Jh, Rich Ss, Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. The Journal of Clinical Psychiatry. ,vol. 56, pp. 556- 559 ,(1995)
M. B. Hamner, W. W. Hong, L. A. Arvanitis, B. G. Miller, C. G. G. Link, Plasma prolactin in schizophrenia subjects treated with Seroquel (ICI 204,636). Psychopharmacology Bulletin. ,vol. 32, pp. 107- 110 ,(1996)
Charles M Beasley Jr, Gary Tollefson, Pierre Tran, Winston Satterlee, Todd Sanger, Susan Hamilton, Olanzapine HGAD Study Group, Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial Neuropsychopharmacology. ,vol. 14, pp. 111- 123 ,(1996) , 10.1016/0893-133X(95)00069-P
Risperidone in the treatment of schizophrenia. American Journal of Psychiatry. ,vol. 151, pp. 825- 835 ,(1994) , 10.1176/AJP.151.6.825
Stephen R. Marder, Facilitating compliance with antipsychotic medication. The Journal of Clinical Psychiatry. ,vol. 59, pp. 21- 25 ,(1998)
M Berk, J Segal, S Brook, Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clinical Neuropharmacology. ,vol. 21, pp. 176- 180 ,(1998)
Mark B. Hamner, George W. Arana, Hyperprolactinaemia in Antipsychotic-Treated Patients CNS Drugs. ,vol. 10, pp. 209- 222 ,(1998) , 10.2165/00023210-199810030-00005
Herman Gerrit Marinus Westenberg, H. M. van Praag, Johan A. den Boer, Advances in the neurobiology of schizophrenia J. Wiley. ,(1995)